Jeanny aragon-ching

Author: aqno

August undefined, 2024

WebDr. Jeanny Aragon-Ching, MD (they/them) is a hematology and oncology specialist in Fairfax, VA. They have received an overall patient experience rating of 5 out of 5. Dr. … WebJeanny B Aragon-Ching Maintenance therapy with immune checkpoint inhibitors (ICIs) has changed the treatment paradigm of metastatic urothelial carcinoma (mUC). The JAVELIN …

challenges and advances in the diagnosis, biology, and treatment …

WebJun 18, 2024 · Dr. Aragon-Ching is a medical oncologist and the clinical program director of the Genitourinary Oncology Program at the Inova Schar Cancer Institute in Virginia. Our full disclosures are available in the show … WebFeb 20, 2024 · Long-term follow-up from the JAVELIN Bladder 100 trial confirms that avelumab 1L maintenance provides similar OS and PFS benefits in pts with advanced UC who are progression free following standard-of-care 1L cisplatin- or carboplatin-based chemotherapy, with an acceptable safety profile. 508 Background: For platinum-eligible … atacama calama

Jeanny B. Aragon-Ching, MD Medical Oncologist in Leesburg, VA

WebJeanny B. Aragon-Ching, MD has been registered with the National Provider Identifier database since May 29, 2008, and her NPI number is 1376701946. Dr. Aragon-Ching certified her NPI information on 09/10/2024. Book an Appointment. To schedule an appointment with Dr. Jeanny B. Aragon-Ching, please call (571) 472-4724. WebDr. Jeanny Aragon-Ching, MD, is an Oncology specialist practicing in FAIRFAX, VA with 26 years of experience. This provider currently accepts 53 insurance plans including … asian mlm

‪Jeanny Aragon-Ching‬ - ‪Google Scholar‬

Dr. Jeanny Aragon-Ching, MD FAIRFAX, VA Oncology

WebJeanny Aragon-Ching, MD is an Oncologist. Read more to learn about Jeanny Aragon-Ching, MD's background, education, and other specialties. WebMar 10, 2024 · March 10, 2024. Sam Chang and Jeanny Aragon-Ching discuss treatment and survival differences in patients with urothelial versus non-urothelial bladder and upper … asian mkt todayWebSep 21, 2024 · Jeanny B. Aragon-Ching, MD, FACP, clinical program director, Genitourinary Cancers, the Inova Schar Cancer Institute, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 ... atacama desert bfbc2

"WebOct 28, 2015 · Aragon-Ching is a well-established clinician and has authored over 60 publications including papers in high-impact journals such as Clinical Cancer Research, Journal of Urology and the Lancet. Thomas Graves, FACHE has joined ISCI as Vice President for Cancer Services and Associate Director for Administration. Mr. " - Jeanny aragon-ching

Jeanny aragon-ching

WebJan 6, 2024 · Jeanny B. Aragon-Ching, MD, FACP, discusses the use of maintenance avelumab as the standard-of-care treatment for patients with locally advanced or metastatic urothelial carcinoma. WebJan 23, 2012 · Dr. Jeanny Aragon-Ching, MD, is a specialist in oncology who treats patients in FAIRFAX, VA. This provider has 26 years of experience and is affiliated with George …

Did you know?

WebAuthor Jeanny B Aragon-Ching 1 Affiliation 1GU Medical Oncology, Inova Schar Cancer Institute, Department of Medicine, Virginia Commonwealth University, Fairfax, VA. Electronic address: [email protected]. PMID: 28625477 DOI: 10.1016/j.urolonc.2024.05.023 Abstract WebOct 30, 2024 · Correspondence to: Jeanny B. Aragon-Ching, MD, FACP. Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute, 8081 Innovation Park Drive, Fairfax, VA, USA. ... Aragon-Ching JB, Rosner IL. Financial toxicity differences between chemical versus surgical androgen deprivation therapy. Transl Androl Urol …

WebMay 15, 2024 · Jeanny B. Aragon-Ching, MD, is the clinical program director of genitourinary cancers at the Inova Schar Cancer Institute. She is board certified in medical oncology, hematology and internal medicine and has a special interest in caring for patients with prostate, bladder, kidney and testicular cancers. Prostate cancer is an extremely common ... WebDec 10, 2024 · Dr. Jeanny Aragon-ching graduated from Other in 1997. Dr. Aragon-ching has one office in Virginia where she specializes in Hematology / Oncology, Hematology …

WebJeanny B. Aragon-Ching; Inger L. Rosner; Translational Andrology and Urology. Published on 01 Oct 2024. 0 views XX downloads; XX citations; 1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100. J.B. Aragon-Ching ... WebMar 10, 2024 · Jeanny Aragon-Ching: Sam, thank you so much and for UroToday, too, for giving us a little bit of insights on the abstract that I presented at GU ASCO. So this is the treatment and survival differences in patients with urothelial versus non-urothelial bladder and upper tract carcinomas and analysis from the National Cancer Database. And as we ...

WebApr 13, 2024 · Results from the JAVELin Bladder 100 study support the use of avelumab as maintenance treatment for people with advanced urothelial cancer whose cancer has shrunk or not grown with first-line chemotherapy. WHAT IS THIS SUMMARY ABOUT? This is a plain language summary of an article originally published in The New England Journal of …

WebUroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology. asian mma womenWebSep 26, 2024 · [8].Aragon-Ching, Jeanny B. “ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment.” Asian journal of andrology, 10.4103/aja202430. 24 May. 2024, doi:10.4103/aja202430 asian mlbWebMar 4, 2024 · Plasmacytoid variant of urothelial carcinoma is a rare subtype of urothelial carcinoma that has poor prognosis. We describe two cases of patients with the plasmacytoid variant of urothelial carcinoma (PVUC) who had initial response to neoadjuvant chemotherapy followed by radical cystoprostatectomy and lymph node … atacama desert animals